Fig. 2.
Absolute numbers of HSCT in Europe from 1990 to 2000 according to main indications.
(A) Allogeneic transplantations for leukemias, lymphoproliferative disorders, and nonmalignant disorders. (B) Autologous transplantations for leukemias, lymphomas, multiple myelomas, breast cancer, and other solid tumors.